Full-Time

Project Portfolio Management Analyst

Enterprise Portfolio Management

Posted on 9/16/2025

Hologic

Hologic

5,001-10,000 employees

Develops medical devices for early detection

Compensation Overview

$88.6k - $138.5k/yr

+ Bonus

Marlborough, MA, USA

In Person

Category
Business & Strategy (1)
Required Skills
ServiceNow
Visio
Requirements
  • Bachelor’s degree in Information Technology, Business Administration, Project Management, or a related field (or equivalent experience)
  • 3+ years of experience in eliciting and documenting business requirements and workflows
  • 3+ years of experience in portfolio management tools administration (minor updates), with Planview (preferred)
  • Experience working within a PMO, IT, or project management environment is a plus
Responsibilities
  • Configure and maintain IT and other departmental dashboards and reports.
  • Responsible for minor system configuration changes such as making updates to existing fields or dropdown values.
  • Works with the development team to ensure the Enterprise Portfolio Management tool functionality aligns with organizational goals and requirements.
  • Collaborate with vendor to determine which integrations are OOB vs. custom. Ensure integrations are configured and working properly (this role does not configure any integrations).
  • Manage user access, roles, and permissions, ensuring compliance with security and governance policies.
  • Monitor tool performance and troubleshoot issues (working with the PPM support team) to ensure seamless operation.
  • Oversee data accuracy and integrity within the enterprise tool, performing regular audits and updates as needed.
  • Develop and maintain custom dashboards, reports, and analytics to provide actionable insights into portfolio performance.
  • Support leadership and stakeholders with data visualization and reporting to drive informed decision-making.
  • Ensure alignment of tool data with organizational KPIs, metrics, and strategic objectives.
  • Develop and document a Governance process for the enterprise tool (working with the Director – IT PMO).
  • Develop best practices for onboarding new areas of the organization that wish to utilize our Enterprise PPM tool.
  • Elicit detailed business requirements and define as-is and to-be processes.
  • Document the requirements (Business Requirements Document) and workflows (Visio).
  • Review the requirements with the development team to ensure accuracy.
  • Ensure the business has executed functional testing in Sandbox and corrected any errors, prior to moving to Production.
  • Continuously stay aware of system performance and recommend or implement enhancements to improve usability and efficiency.
  • Collaborate with project managers, portfolio managers, and PMO leaders across the organization to optimize processes within the enterprise tool to enable their needs.
  • Identify opportunities to streamline workflows and enhance tool utilization ensuring minimal disruption to the business.
  • Stay current on the enterprise product capabilities and industry best practices to recommend improvements.
  • Provide training to new and existing users on tool functionality, processes, and best practices.
  • Develop user guides, FAQs, and other training documentation to support tool adoption and effective usage.
  • Serve as the first point of contact for dashboard/reporting issues.
  • Provide training on how to open ServiceNow tickets for the appropriate type of request/issue (Enhancement, Technical Issue, Access Requests, etc.)
  • Function as the main POC with the vendor and escalate issues, as necessary.
  • Partner with cross-functional teams to understand business needs and translate them into tool requirements.
  • Act as a liaison between the organization and enterprise portfolio vendor representatives for tool enhancements, upgrades, and support.
  • Support change management efforts related to tool adoption and updates, ensuring smooth transitions for users.
  • Support portfolio management processes by enabling accurate data capture and reporting.
  • Ensure that the enterprise portfolio tool supports portfolio prioritization, resource planning, and project execution.
  • Collaborate with PMO teams to ensure alignment between tool functionality and broader organizational strategies.
  • Monitor portfolio health and provide recommendations to improve resource allocation and project prioritization.
Desired Qualifications
  • Project management certifications such as PMP, PRINCE2, or Agile certifications (e.g., Certified ScrumMaster) are a plus

Hologic develops medical technology to improve health through early detection and treatment. It designs, manufactures, and sells devices and diagnostic tests for breast and skeletal health, general diagnostics, GYN surgery, and medical aesthetics, sold to hospitals, labs, and providers with related services. Products enable screening, imaging, and guiding treatment in clinical settings. Its goal is to improve health outcomes by providing accurate diagnostics and reliable tools to support healthcare providers worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Santa Clara, null

Founded

1985

Simplify Jobs

Simplify's Take

What believers are saying

  • GYN Surgical revenues grew 7.5% to $180.8M in Q1 2026 from MyoSure and Fluent.
  • $18.3B Blackstone-TPG acquisition in April 2026 funds AI and oncology R&D.
  • 3DQuorum AI reduces mammography slices while maintaining diagnostic accuracy.

What critics are saying

  • Blackstone-TPG cuts R&D to service debt, stalling AI mammography within 12 months.
  • CEO MacMillan retires post-April 2026 deal, disrupting GYN surgical integration.
  • US-China tariffs slash Asia-Pacific ThinPrep revenues by 2.7% in Q1 2026.

What makes Hologic unique

  • Hologic leads women's health with ThinPrep Pap test and Aptima HPV assays.
  • Genius AI Detection identifies 90% of invasive lobular breast cancers.
  • Sonata System from 2025 Gynesonics acquisition treats uterine fibroids ultrasonically.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Performance Bonus

Company News

Hologic
Apr 20th, 2026
New evidence backs Hologic's ai-powered mammography technology for detecting challenging cancers.

New evidence backs Hologic's ai-powered mammography technology for detecting challenging cancers. Results highlight AI's potential to aid radiologists in identifying diverse breast cancer subtypes, including invasive lobular cancer MARLBOROUGH, Mass., April 20, 2026 - New research on Hologic's AI-driven breast cancer detection technologies, including a study focused on invasive lobular cancer, was presented at the Society of Breast Imaging (SBI) Symposium over the weekend in Seattle, Washington. "Invasive lobular cancers are more challenging to detect on a mammogram because of their unique characteristics," said Mark Horvath, President of Breast & Skeletal Health Solutions at Hologic. "In the study, AI maintained high sensitivity for flagging these cancers, including some that had been interpreted as negative at a prior screening. These data add to a growing body of evidence that AI can act as a powerful supportive tool for radiologists as they review the full spectrum of breast cancers." In this retrospective, single-center study, researchers at Massachusetts General Hospital in Boston reviewed invasive lobular cancer cases diagnosed over a 10-year period and grouped them into two categories: those detected by a radiologist during a routine screening exam (195 total) and "false negatives" that were diagnosed within a year of a routine screening exam initially interpreted as negative (44 total). Researchers then used Hologic's Genius AI(R) Detection solution to retrospectively analyze all 239 cases. In this cohort, the technology identified and correctly localized close to 90% of the confirmed invasive lobular cancers.[1] New research suggests that, on average, 1 in 20 women worldwide will be diagnosed with breast cancer in their lifetime and, that if current rates continue, by 2050 there will be 3.2 million new breast cancer cases and 1.1 million breast cancer-related deaths per year.[2] About 10-15% of all breast cancers are invasive lobular cancers,[3] while ductal cancers that originate in the milk ducts of the breast - such as invasive ductal carcinoma and ductal carcinoma in situ - occur more commonly. Invasive lobular cancer arises in the milk-producing glands (lobules) of the breast and, because of its unique biology and tendency to grow in a linear pattern, it may be more challenging to see on mammography. This may lead to later detection and a more advanced stage at diagnosis. The AI algorithm also identified 43% of the invasive lobular cancer cases initially interpreted during routine screening as negative.[1] Of note, as a retrospective analysis at a single institution, the study did not evaluate how use of AI in real time clinical practice would affect recall rates, biopsy outcomes or patient management. Also at the Society of Breast Imaging Symposium, Hologic hosted a lunch and learn discussion with breast imaging experts focused on implementation of 3DQuorum(R) imaging technology, which uses AI to reduce the number of 3D imaging "slices" radiologists need to review without compromising image quality, sensitivity or accuracy.[4,5] Study Limitations The MGH study did not assess false-positive rates, recall rates or biopsy outcomes, and its single-center design may limit generalizability. AI performance was evaluated retrospectively and did not influence real-time radiologist decision-making; therefore, the observed gains represent a theoretical upper bound rather than a measured clinical impact. Additionally, the cohort included only patients with invasive lobular cancer, precluding comparison with other histologic subtypes. About Genius AI Detection Hologic's Genius AI Detection solution is an innovative mammography screening technology designed to locate lesions likely to represent breast cancer. Suspicious areas are highlighted at radiologists' workstations for concurrent reading to support smart, decisive interpretation. Hologic's deep learning algorithm is fed by the accumulation of a large, diverse patient base, providing rich insight and intelligence. For more information, please visit Genius AI Detection Technology. About Hologic, Inc. Hologic, Inc. is a global leader in women's health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with Hologic Inc. on LinkedIn, Facebook, X, Instagram and YouTube. Forward-Looking Statements This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based. Hologic, The Science of Sure, Genius AI and 3DQuorum are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. Media Contact: Bridget Perry Senior Director, Corporate Communications (+1) 508.263.8654 [email protected]&

Yahoo Finance
Apr 7th, 2026
Hologic delivers weakest Q4 among imaging and diagnostics stocks with revenue miss

GE HealthCare delivered the strongest fourth-quarter performance among medical devices and imaging stocks, whilst Hologic posted the weakest results against analyst estimates, according to a sector review. The four medical devices and imaging companies tracked reported slower fourth-quarter growth overall, though revenues collectively beat consensus estimates by 3.5%. Share prices have struggled since results, falling an average of 13.5%. Hologic, which develops diagnostic products and medical imaging systems focused on women's health, reported revenues of $1.05 billion, up 2.5% year on year but missing analysts' expectations by 2.1%. The company significantly missed both revenue and earnings estimates. Despite the disappointing results, Hologic shares have risen 1.4% since reporting and currently trade at $76.05. GE HealthCare, spun off from General Electric in 2023, outperformed peers in the quarter.

MedTech Dive
Apr 6th, 2026
Hologic CEO Steve MacMillan to retire after go-private deal.

Hologic CEO Steve MacMillan to retire after go-private deal. The $18.3 billion acquisition by Blackstone and TPG is expected to close Tuesday. Published April 6, 2026 Dive brief: * Hologic CEO Steve MacMillan will retire after the company is acquired by funds managed by Blackstone and TPG. * The go-private deal, announced in October, values the maker of mammography machines, cervical cancer screening tests and other diagnostics tools at $18.3 billion. * Hologic said Monday that it has received all needed regulatory approvals for the transaction and expects the acquisition to close Tuesday. Hologic plans to name its next CEO when the acquisition closes. Dive insight: MacMillan, 62, has been CEO of the firm since 2013. During his time at the company, Hologic's revenue increased by 65%, its share price more than tripled, and its workforce grew by more than 1,500 people. Hologic reported $3.26 billion in revenue in its 2025 fiscal year ending in September. Amy Wendell, Hologic's lead independent director, said in a statement that MacMillan "forged a dramatic turnaround shortly after joining the Company, led us through years of consistent growth, drove our unprecedented response to the COVID pandemic, and is guiding us through a successful go-private transaction." Prior to working for Hologic, MacMillan was CEO of Stryker, and held senior executive roles at Pharmacia and Johnson & Johnson. With the take-private agreement by Blackstone and TPG, Hologic's stockholders would receive $76 per share, and up to $3 per share more if the company meets certain revenue goals for its breast health business in fiscal years 2026 and 2027. Hologic will be delisted from the Nasdaq after the deal closes. The company will keep its current headquarters in Marlborough, Massachusetts.

AktienSensor
Mar 31st, 2026
Hologic secures record-low debt financing to boost growth and innovation

Hologic has completed a debt financing package featuring reportedly record-low borrowing costs, among the tightest spreads for leveraged loans in the past decade. The medical technology company structured the deal as a senior secured leveraged-loan facility, though exact figures were not disclosed. The financing aims to reduce debt-service costs, improve cash flow, and provide flexibility for acquisitions and research and development investment. Hologic operates in diagnostic imaging and laboratory testing, competing with Siemens Healthineers and GE Healthcare whilst focusing on precision oncology diagnostics and AI-driven imaging. The deal positions Hologic to pursue strategic partnerships and potential acquisitions in the consolidating medical diagnostics sector, though risks include interest-rate volatility and covenant constraints.

Yahoo Finance
Mar 19th, 2026
Hologic shares trade 1.2% below Blackstone-TPG's $76 buyout offer after shareholder approval

Hologic shares closed at $75.05, trading 1.2% below Blackstone and TPG's $76 per share buyout offer announced in October 2025. The deal includes a contingent value right worth up to $3 per share, tied to Breast Health revenue targets, for a total potential value of $79 per share. Shareholders approved the take-private transaction at a February meeting. The Massachusetts-based medical technology company, which develops diagnostic and imaging products for women's health, has gained 0.7% year-to-date, outperforming peers GE HealthCare and Becton Dickinson. However, Hologic's valuation appears stretched at 3.84 times forward price-to-sales, above its sector average of 2.28 times. First-quarter fiscal 2026 results showed weakness in its Diagnostics division, with revenues declining 2.7% in constant currency.

INACTIVE